A trivalent protein-based pan-Betacoronavirus vaccine elicits cross-neutralizing antibodies against a panel of coronavirus pseudoviruses.
Syamala Rani ThimmirajuRakesh AdhikariJeAnna R ReddMaria Jose VillarJungsoon LeeZhuyun LiuYi-Lin ChenSuman SharmaAmandeep KaurNestor L UzcateguiShannon E RoncaWen-Hsiang ChenJason T KimataBin ZhanUlrich StrychMaria-Elena BottazziPeter J HotezJeroen PolletPublished in: NPJ vaccines (2024)
The development of broad-spectrum coronavirus vaccines is essential to prepare for future respiratory virus pandemics. We demonstrated broad neutralization by a trivalent subunit vaccine, formulating the receptor-binding domains of SARS-CoV, MERS-CoV, and SARS-CoV-2 XBB.1.5 with Alum and CpG55.2. Vaccinated mice produced cross-neutralizing antibodies against all three human Betacoronaviruses and others currently exclusive to bats, indicating the epitope preservation of the individual antigens during co-formulation and the potential for epitope broadening.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- dengue virus
- endothelial cells
- binding protein
- monoclonal antibody
- dna methylation
- drug delivery
- induced pluripotent stem cells
- dendritic cells
- gene expression
- immune response
- protein protein
- amino acid
- coronavirus disease
- zika virus
- insulin resistance
- dna binding
- transcription factor
- risk assessment
- respiratory tract